Taiwan severe asthma biologic registry study
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study is creating a registry to track the long-term safety and effectiveness of biologic treatments for severe asthma in Taiwan. If you are taking a biologic like omalizumab, mepolizumab, or benralizumab, joining this registry helps doctors learn how well these medicines work over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of severe asthma, reviewed by the health authorities or a study board.
- You must be currently treated with one of these biologic medications: omalizumab, mepolizumab, or benralizumab, and have started it after January 1, 2020.
- You cannot have used any biologic medication before January 1, 2020.
- You should not have other significant lung diseases like COPD, bronchiectasis, or pulmonary fibrosis, or major risk factors like smoking.
- You must agree to participate and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how biologic medicines (special injections or infusions) are used to treat severe asthma in Hong Kong. It may help researchers understand why some people stop or switch these treatments.
This study looks at how asthma affects people in China and tries to find patterns that might help predict which treatments work best. If you have asthma and are between 18 and 75, you may be able to join.
This study collects health information from adults with severe asthma to better understand the condition and improve treatment. Your participation involves sharing medical data to help researchers learn more about what works best for severe asthma.
This study tests if a personalized exercise program can help adults with severe asthma who are starting a new biologic treatment. It aims to improve symptoms and quality of life.
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
This trial looks at people with severe asthma that is hard to control. It aims to find and treat specific health problems that make asthma worse, by doing a detailed check-up and using treatments that are right for you.
Hear when a new Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.